Testosterone plays a critical role in male sexual functioning but can also impact bone mass, fat distribution, muscle mass, ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Alright, listen to me. This one is one that everyone’s going to give up on. Then one day, it’s going to be up 300, I’m not ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...